Immage Biotherapeutics Corp. (IMMG) Stock
Presently, Immage Biotherapeutics Corp. lacks substantial business operations.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About Immage Biotherapeutics Corp.
Presently, Immage Biotherapeutics Corp. lacks substantial business operations. Historically, its endeavors centered on the creation of cutting-edge immunotherapy biologics designed to combat diverse cancer types across the United States. Established in 2012, the entity was initially known as Epicure Charcoal, Inc., rebranding to Immage Biotherapeutics Corp. in June 2015. Its corporate headquarters are situated in Bethesda, Maryland, and it operates as a subsidiary of Coventry International Limited.
Immage Biotherapeutics Corp. (IMMG) stock trades at $0.00 with a market capitalization of $15174. The stock is valued at a price-to-earnings (P/E) ratio of -0.07, price-to-book of 0.08, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.
On profitability, Immage Biotherapeutics Corp. generates a return on equity (ROE) of -200.39%, return on capital employed of -115.58%, an operating margin of 0.00%, a net profit margin of 0.00%.
Official website: www.immagebio.com